Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy

Leprosy Review

Volumn 77, Issue 1, 2006, Pages 25-33

  Sundar Rao, P S S ^a   Sugamaran, D S T ^a   Richard, J ^a   Smith, W C S ^b  

^a Schieffelin Institute of Health Research & Training   (India)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISOLONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; HUMAN; INDIA; LEPROSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REVERSAL REACTION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDIA; LEPROSTATIC AGENTS; LEPROSY; MALE; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDNISOLONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33646478879     PISSN: 03057518     EISSN: 03057518     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Lienhardt C, Fine PEM. Type 1 reaction, neuritis and disability in leprosy. What is the current epidemiological situation. Lepr Rev, 1994; 65: 9-33.
2. Croft RP, Nicholls PG, Steyerberg EW et al. A clinical prediction rule for nerve function impairment in leprosy patients. Lancet, 2000; 355: 1603-1606.
3. Lowe J. ACTH and cortisone in treatment of complications of leprosy. BMJ, 1952; 2(4787): 746-749.
4. Pearson JMH. The use of corticosteroids in leprosy. Lepr Rev, 1981; 52: 293-298.
5. Imkamp FMJH. Standardised schemes for steroid treatment in EWL and reversal reactions. Int J Lepr, 1985; 53: 313-317.
6. Kiran KU, Stanley JNA, Pearson JMH. The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardised steroid regimen. Lepr Rev, 1985; 56: 127-134.
7. Kiran KU, Hogeweg M, Suneetha S. Treatment of recent facial nerve damage with lagoththalmos, using a semi-standardised steroid regimen. Lepr Rev, 1991; 62: 150-154.
8. World Health Organisation. WHO Expert Committee on Leprosy. WHO Technical Report Series, 1998; 874: 22-23.
9. Lockwood DNJ, Vinayakumar S, Stanley JMA et al. Clinical features and outcome of reversal (Type 1) reactions in Hyderabad, India. Int J Lepr, 1993; 61: 8-15.
10. van Brakel WH, Khawas IB. Nerve function impairment in leprosy: an epidemiological and clinical study - part 2: results of steroid treatment. Lepr Rev, 1996; 67: 104-118.
11. Sugumaran DST. Steroid therapy for paralytic deformities in leprosy. Int J Lepr, 1997; 65: 337-344.
12. Croft RP, Nicholls PG, Richards JH, Smith WCS. The treatment of acute nerve function impairment in leprosy: results from a prospective cohort study in Bangladesh. Lepr Rev, 2000; 71: 154-168.
13. Naafs B, Pearson JMH, Wheate HW. Reversal reaction: the prevention of permanent nerve damage: comparison of short and long term steroid treatment. Int J Lepr, 1979; 47: 7-12.
14. Richardus JH, Withington SG, Anderson AM et al. Adverse events of standardised regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the TRIPOD trials. Lepr Rev, 2003; 74: 319-327.
15. Britton WJ, Lockwood DNJ. Leprosy. Lancet, 2004; 363: 1209-1219.
16. Roland M, Torgerson DJ. Understanding controlled trials: what are pragmatic trials. BMJ, 1998; 316: 285.
17. Smith WCS, Anderson AM, Withington SG et al. Steroid prophylaxis for the prevention of nerve function impairment in leprosy: a randomised placebo controlled trial (TRIPOD 1). BMJ, 2004; 328: 1459-1465.